The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Bill to Amend Immunization Act Submitted to Diet
Japan’s Cabinet on October 27 adopted and submitted to the Diet a draft bill to amend the Immunization Act that would effectively allow the government to shoulder liability risks for health damages that might be caused by coronavirus vaccines. “We’d…
To read the full story
Related Article
- Japan Diet Clears Immunization Bill
December 2, 2020
- Japan Diet Expected to Enact Immunization Bill on Dec. 2
November 27, 2020
- Lower House Passes Immunization Act Amendment Bill
November 20, 2020
- Lower House Health Committee Starts Debate on Immunization Bill; Minister Says to Publish PAFSC Meeting Minutes ASAP
November 12, 2020
- PM Suga Vows Transparency in COVID-19 Vaccine Review as Immunization Bill Enters Diet Deliberations
November 11, 2020
- Bill to Amend Immunization Act to Enter Lower House Deliberations on November 10
November 6, 2020
- Vice Health Minister Vows to Work on Law Amendment to Set Up Sound Vaccination Scheme
October 20, 2020
- Japan Cannot Boast of Its Development Status of COVID-19 Vaccines/Drugs: LDP Health Committee Chair
October 20, 2020
- LDP’s Health Committee OKs Bill to Amend Immunization Act
October 16, 2020
REGULATORY
- Japan to Cut Drug Prices by 0.86% in FY2026; Central Govt Savings Seen at 105 Billion Yen
December 25, 2025
- Japan Growth Strategy Council to Set Up Drug Discovery Working Group
December 25, 2025
- Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
- Takeda Plans January Rollout of Overseas Plasma-Derived Ig amid Suspension
December 25, 2025
- Japan Panel OKs Label Warning Update for Labor Inducers to Mention Epidural Births
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…